medigraphic.com
Instituto Nacional de Salud Pública

2020, Número 3

<< Anterior Siguiente >>

salud publica mex 2020; 62 (3)


Epidemiología descriptiva y cambios en la frecuencia de tumores astrocíticos en el Instituto Nacional de Neurología y Neurocirugía de México

Aguirre-Cruz L, Rodríguez-Pérez CE, de la Cruz-Aguilera DL, Acosta-Castillo GI, Ruano-Calderón L, Martínez-Moreno M, Sotelo J

Idioma: Español
Referencias bibliográficas: 34
Paginas: 255-261
Archivo PDF: 393.05 Kb.


RESUMEN

Objetivo. Determinar distribución, localización y cambios de la frecuencia de tumores astrocíticos (TA) en un instituto mexicano de neurología. Material y métodos. Se revisaron los registros institucionales de TA de cinco décadas. Se compararon las relaciones TA/egresos quirúrgicos (EQ) y TA/total de tumores del sistema nervioso central (TSNC) de 1995 a 2014. Resultados. Se analizaron 2 287 TA (1 356 en hombres y 931 en mujeres). El glioma más común fue el glioblastoma multiforme (GBM), que estuvo presente en adultos jóvenes con una frecuencia mayor a la reportada en otros estudios. La relación TA/EQ y TA/TNSC fue similar entre 1995 y 2014. Conclusiones. En general, la frecuencia de TA atendidos en el Instituto es similar a la reportada internacionalmente. No obstante, los casos de TA en el subgrupo de adultos jóvenes con GBM son más frecuentes (40%) que las incidencias reportadas en otros estudios (menores al 5%). No se encontró variación significativa en la frecuencia de TA durante las últimas dos décadas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Riemenschneider MJ, Reifenberger G. Astrocytic tumors. Recent Results Cancer Res. 2009;171:3-24. https://doi.org/10.1007/978-3-540-31206-2_1

  2. Liu R, Page M, Solheim K, Fox S. Quality of life in adults with brain tumors: current knowledge and future directions. Neuro Oncol. 2009;11(3):330-9. https://doi.org/10.1215/15228517-2008-093

  3. Scheithauer BW, Hawkins C, Tihan T, VandenBerg CR, Burger PC. Astrocytic tumours. En: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of tumours of the central nervous system. Lyon: IARC, 2007:13-50.

  4. Brzozowska A, Torun A, Mazurkiewicz M. The impact of surgery on the efficacy of adjuvant therapy in glioblastoma multiforme. Adv Clin Exp Med. 2015;24(2):279-87. https://doi.org/10.17219/acem/40456

  5. Brandes AA, Tosoni A, Franceschi E, Reni M, Gatta G, Vecht Ch. Glioblastoma in adults. Crit Rev Oncol Hematol. 2008;67(2):139-52. https://doi. org/10.1016/j.critrevonc.2008.02.005

  6. Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012; 48(10):1532-42. https://doi.org/10.1016/j.ejca.2011.12.013

  7. Ho VK, Reijneveld JC, Enting RH, Bienfait HP, Robe P, Baumert BG, et al. Changing incidence and improved survival of gliomas. Eur J Cancer. 2014;50(13):2309-18. https://doi.org/10.1016/j.ejca.2014.05.019

  8. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002;4(4):278-99. https://doi.org/10.1093/neuonc/4.4.278

  9. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet. 2012;379(9830):1984-96. https:// doi.org/10.1016/S0140-6736(11)61346-9

  10. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803-20. https://doi.org/10.1007/s00401-016-1545-1

  11. Monteiro G, Koifman SM. Brain tumors mortality in Brazil, 1980- 1998. Cad Saúde Pública, Rio de Janeiro. 2003;19(4):1139-51. https://doi. org/10.1590/s0102-311x2003000400035

  12. Díaz TV, Yáñez LA, Ponce OC, Villegas R, Pastén JA. Tendencia de la mortalidad por tumores cerebrales malignos en Chile: Análisis de tasas. Rev Chil Neuro-Psiquiatr. 2006;44(4):263-70. https://doi.org/10.4067/ S0717-92272006000400005

  13. Aguirre-Cruz L, Rangel-López E, Cruz-Aguilera DL, Rodríguez-Pérez CE, Ruano L, Velásquez-Pérez L, et al. Historical distribution of central nervous system tumors in the Mexican National Institute of Neurology and Neurosurgery. Salud Publica Mex. 2016;58(2):171-8. https://doi. org/10.21149/spm.v58i2.7786

  14. Piñeros M, Sierra MS, Izarzugaza MI, Forman D. Descriptive epidemiology of brain and central nervous system cancers in Central and South America. Cancer Epidemiol. 2016;44(suppl 1):S141-S149. https://doi. org/10.1016/j.canep.2016.04.007

  15. Bailey P, Cushing HW. A classification of the tumors of the glioma group on a histogenetic basis with a correlated study of prognosis. Philadelphia, PA: J. B. Lippincott, 1926.

  16. Zülch KJ. Histological typing of tumours of the central nervous system. Ginebra: World Health Organization, 1979.

  17. Kleihues P, Burger PC, Scheithauer BW (eds). Histological typing of tumours of the central nervous system. Springer, Heidelberg: World Health Organization international histological classification of tumours, 1993. https://doi.org/10.1007/978-3-642-84988-6

  18. Daumas-Duport C, Scheithauer B, O’Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer. 1988;62(10):2152-65. https://doi.org/10.1002/1097- 0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t

  19. Kleihues P, Cavenee WK, eds. World Health Organization classification of tumors: Pathology and genetics of tumors of the nervous system. Lyon: IARC Press, 2000.

  20. Scheithauer BW. Development of the WHO Classification of Tumors of the Central Nervous System: A Historical Perspective. Brain Pathol. 2009;19(4):551-64. https://doi.org/10.1111/j.1750-3639.2008.00192.x

  21. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin LH, Parkin DM, et al. International Classification of diseases for Oncology ICD-O-3. 3rd ed. Ginebra: World Health Organization, 2000 [citado junio 2019]. Disponible en: https://apps.who.int/iris/handle/10665/42344

  22. World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th Revision ICD-10-WHO Version, Chapter II Neoplasms (COO-D48); Malignant neoplasm of eye, brain and other parts of central nervous system (C69-C72). Ginebra: WHO, 2016 [citado junio 2019]. Disponible: https://icd.who.int/browse10/2016/ en#/C69-C72

  23. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-58. https://doi.org/10.1002/sim.1186

  24. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosed in United States in 2010-2014. Neuro- Oncology. 2017;19(suppl 5):1-88. https://doi.org/10.1093/neuonc/nox158

  25. Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber- Mösenbacher U, et al. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol. 2009;95:401-11. https://doi.org/10.1007/s11060-009-9938-9

  26. Jung KW, Ha J, Lee SH, Won YJ, Yoo H. An updated nationwide epidemiology of primary brain tumors in republic of Korea. Brain Tumor Res Treat. 2013;1(1):16-23. https://doi.org/10.14791/btrt.2013.1.1.16

  27. Fuentes-Raspall R, Vilardell L, Perez-Bueno F, Joly C, Garcia-Velasco M, Marcos-Gragera R. Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005. J Neurooncol. 2011;101:117-23. https://doi.org/10.1007/s11060-010-0240-7

  28. Larjavaara S, Mäntylä R, Salminen T, Haapasalo H, Raitanen J, Jääskeläinen J, et al. Incidence of gliomas by anatomic location. Neuro Oncol. 2007;9(3):319-25. https://doi.org/10.1215/15228517-2007-016

  29. Zada G, Bond AE, Wang Y-P, Giannotta SL, Deapen D. Incidence trends in the anatomic location of primary malignant brain tumors in the United States: 1992-2006. World Neurosurg. 2012;77(3-4):518-24. https://doi. org/10.1016/j.wneu.2011.05.051

  30. Brodbelt A, Greenberg D, Winters T, Williams M, Vernon S, Collins PV, et al. Glioblastoma in England: 2007-2011. Eur J of Cancer. 2015;51(4):533- 42. https://doi.org/10.1016/j.ejca.2014.12.014

  31. Sadetzki S, Zach L, Chetrit A, Nass D, Hoffmann C, Ram Z, et al. Epidemiology of gliomas in Israel: a nationwide study. Neuroepidemiology. 2008;31(4):270. https://doi.org/10.1159/000165366

  32. Gousias K, Markou M, Voulgaris S, Goussia A, Voulgari P, Bai M, et al. Descriptive epidemiology of cerebral gliomas in northwest Greece and study of potential predisposing factors, 2005-2007. Epidemiology. 2009;33(2):89-95. https://doi.org/10.1159/000222090

  33. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-386. https://doi.org/10.1002/ijc.29210

  34. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492




2020     |     www.medigraphic.com